I will accept. The stock rose from 2.2x till today is due to previous speculation of acquisition (first appeared in the edge 19july). If acquisition fails, the price will drop and will take long to recover. Malaysia pharmaceuticals only do generic medicines and this space is very competitive. Another segment of company is distribution, this has lower margin and market is being absorbed by zuellig and dksh. Simply put, there isnt any catalyst for *big* increase in profit in near to medium term (small increase is certain). Company cough syrup is the only non-replaceable so far in the market.